Diagnostics and research stocks with the lowest PE ratio

Ranked

20

of 74 diagnostics and research stocks we cover

Median

39.3×

Lowest

24.2×

LNTH

Range

24.2× to 166×

#	Company	PE	PE vs its 10 years	Revenue growth (TTM)	Market cap
1	LNTHLantheus	24.2×	52nd pct	+2.3%	$6.5B
2	DGXQuest Diagnostics	25.7×	99th pct	+9.1%	$26.7B
3	LHLabcorp	27.2×	73rd pct	+6.4%	$26.7B
4	CDNACareDx	33.4×	99th pct	+34.4%	$3.6B
5	AAgilent Technologies	34.0×	58th pct	+8.6%	$48.8B
6	VCYTVeracyte	34.2×	13th pct	+17.3%	$3.9B
7	IQVIQVIA	34.7×	49th pct	+8.2%	$46B
8	TMOThermo Fisher Scientific	35.5×	65th pct	+8.3%	$249.1B
9	MTDMettler-Toledo International	37.6×	55th pct	+6.9%	$33.5B
10	MEDPMedpace	39.2×	69th pct	+24.7%	$18.7B
11	IDXXIDEXX Laboratories	39.4×	3rd pct	+12.8%	$44.1B
12	DHRDanaher	40.9×	82nd pct	+4.6%	$162B
13	BIOBio-Rad Laboratories	44.8×	56th pct	+1.4%	$9.9B
14	ILMNIllumina	50.1×	48th pct	+4.9%	$40.7B
15	RVTYRevvity	75.6×	93rd pct	+4.1%	$17.7B
16	CAICaris Life Sciences	86.5×	n/a	+85.4%	$9B
17	NRCNRC Health	87.7×	100th pct	−0.2%	$485.1M
18	WATWaters	113×	94th pct	+52.5%	$44.6B
19	ICCCImmucell	128×	87th pct	+8.5%	$93.1M
20	BLLNBillionToOne	166×	n/a	+90.1%	$5.1B

Not ranked: 49 with a loss over the last year, 1 with a quarter missing, 1 with not a meaningful number. 3 companies whose data behind this number has a caveat are left out until it is checked.

A ranking of numbers, not a recommendation. A low multiple can be a bargain or a business in trouble: open the company to see which.